The main reason for this may be that the key mechanism of the EGFR antibody is achieved by blocking the EGFR signaling pathway when accumulating around the tumor, whereas gene mutations and amplifications of the EGFR downstream signaling pathways are frequently noted in ESCC (Song et al., 2014; Zhou et al., 2017). The gene discussed is EGFR; the disease is neoplasm.